Commonground
Senior Moderator
Decision comes shortly after rejection sparked major controversy
Feb. 18, 2026
WASHINGTON — The Food and Drug Administration reversed course and told Moderna it would review its application for a new flu vaccine, the company announced Wednesday.
The agency told Moderna earlier this month that it would not review the submission because of a dispute over the design of a clinical trial. The decision was made by top FDA official Vinay Prasad, who STAT previously reported had overruled career scientists in the vaccine center.
continued: https://www.statnews.com/2026/02/18/fda-moderna-reverse-course-flu-vaccine/
Feb. 18, 2026
WASHINGTON — The Food and Drug Administration reversed course and told Moderna it would review its application for a new flu vaccine, the company announced Wednesday.
The agency told Moderna earlier this month that it would not review the submission because of a dispute over the design of a clinical trial. The decision was made by top FDA official Vinay Prasad, who STAT previously reported had overruled career scientists in the vaccine center.
continued: https://www.statnews.com/2026/02/18/fda-moderna-reverse-course-flu-vaccine/